December 2016

New Product - Taltz

Taltz (ixekizumab (rch)) is a humanised IgG4 monoclonal antibody with neutralising activity against interleukin-17A (IL-17A). Elevated levels of IL-17A have been implicated in the pathogenesis of a variety of autoimmune diseases. In psoriasis, the IL-17A ligand plays a major role in driving excess keratinocyte proliferation and activation. Neutralisation of IL-17A by ixekizumab inhibits these actions. Taltz is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is available as a 1 mL single dose prefilled pen containing 80 mg/1 mL of ixekuzimab in packs of 1’s and 2’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629